Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges DOI Creative Commons
Man Wang, Fei Yu, Yuan Zhang

et al.

Molecular Cancer, Journal Year: 2025, Volume and Issue: 24(1)

Published: Jan. 18, 2025

Clinically, multimodal therapies are adopted worldwide for the management of cancer, which continues to be a leading cause death. In recent years, immunotherapy has firmly established itself as new paradigm in cancer care that activates body's immune defense cope with cancer. Immunotherapy resulted significant breakthroughs treatment stubborn tumors, dramatically improving clinical outcome patients. Multiple forms immunotherapy, including checkpoint inhibitors (ICIs), adoptive cell therapy and vaccines, have become widely available. However, effectiveness these immunotherapies is not much satisfying. Many patients do respond disease recurrence appears unavoidable because rapidly evolving resistance. Moreover, can give rise severe off-target immune-related adverse events. Strategies remove hindrances mainly focus on development combinatorial or exploitation novel immunotherapeutic mediations. Nanomaterials carrying anticancer agents target site considered practical approaches treatment. Nanomedicine combined offers possibility potentiate systemic antitumor immunity facilitate selective cytotoxicity against cells an effective safe manner. A myriad nano-enabled currently under investigation. Owing gaps between preclinical studies, nano-immunotherapy faces multiple challenges, biosafety nanomaterials trial design. this review, we provide overview summarize evidence indicating how nanomedicine-based increase efficacy immunotherapies. We also discuss key challenges emerged era nanotechnology-based immunotherapy. Taken together, combination drawing increasing attention, it anticipated will achieve desired success therapy.

Language: Английский

Stealth and pseudo-stealth nanocarriers DOI Creative Commons

Panyue Wen,

Wendong Ke,

Anjaneyulu Dirisala

et al.

Advanced Drug Delivery Reviews, Journal Year: 2023, Volume and Issue: 198, P. 114895 - 114895

Published: May 19, 2023

Language: Английский

Citations

111
Nanozyme-based pollutant sensing and environmental treatment: Trends, challenges, and perspectives DOI Creative Commons
Ragini Singh, Akhela Umapathi,

Gaurang Patel

et al.

The Science of The Total Environment, Journal Year: 2022, Volume and Issue: 854, P. 158771 - 158771

Published: Sept. 13, 2022

Language: Английский

Citations

100
Tumour‐derived extracellular vesicle membrane hybrid lipid nanovesicles enhance siRNA delivery by tumour‐homing and intracellular freeway transportation DOI Creative Commons
Xin Zhou,

Yunqiu Miao,

Ying Wang

et al.

Journal of Extracellular Vesicles, Journal Year: 2022, Volume and Issue: 11(3)

Published: March 1, 2022

Abstract Extracellular vesicles (EVs) have been proved a promising small interfering RNA (siRNA) delivery vehicle to mediate gene‐silencing. Tumour‐derived extracellular (TDEVs) as genetic exchange vectors in the tumour microenvironment, enable intercellular communication for wide range of endogenous cargo molecules, such RNAs and proteins. However, oncogenic TDEVs limits their application siRNA cancer therapy. Herein, we isolated from hepatocellular carcinoma (HCC) cells derived TDEV membranes by abandoning content. Innovative membrane hybrid lipid nanovesicles (LEVs) were then fabricated fusion phospholipids realize precise tumours highly efficient transfection siRNA. The endow LEVs with ‘homing’ targeting ability, facilitating specific internalisation into parent HCC primarily through heparan sulfate proteoglycan‐mediated pathways. Unlike conventional lipid‐based nanovesicles, can bypass endosomal degradation pathway, boost Golgi endoplasmic reticulum (ER) intracellular ‘freeway’ transportation, achieving 1.7‐fold improvement efficiency compared liposomes. Additionally, loaded demonstrated enhance antitumour efficacy bearing mice effective gene silencing sites. Our results highlight potential membrane‐derived an advanced strategy

Language: Английский

Citations

98
Where should siRNAs go: applicable organs for siRNA drugs DOI Creative Commons

In–Sook Ahn,

Chanhee S. Kang,

Jinju Han

et al.

Experimental & Molecular Medicine, Journal Year: 2023, Volume and Issue: 55(7), P. 1283 - 1292

Published: July 10, 2023

RNA interference mediated by small interfering RNAs (siRNAs) has been exploited for the development of therapeutics. siRNAs can be a powerful therapeutic tool because working mechanisms are straightforward. determine targets based on their sequence and specifically regulate gene expression target gene. However, efficient delivery to organ long an issue that needs solved. Tremendous efforts regarding siRNA have led significant progress in drug development, from 2018 2022, total five drugs were approved treatment patients. Although all FDA-approved hepatocytes liver, siRNA-based targeting different organs clinical trials. In this review, we introduce market candidates trials cells multiple organs. The eye, skin preferred targeted siRNAs. Three or more phase 2 3 suppress these On other hand, lungs, kidneys, brain challenging with relatively few We discuss characteristics each related advantages disadvantages strategies overcome barriers delivering organ-specific progressed

Language: Английский

Citations

78
Exosomes as Drug Carriers in Anti-Cancer Therapy DOI Creative Commons
Lan Chen, Li Wang, Lingling Zhu

et al.

Frontiers in Cell and Developmental Biology, Journal Year: 2022, Volume and Issue: 10

Published: Jan. 26, 2022

Over the years, there has been a high demand for developing new safe and effective drug carriers cancer therapy. Emerging studies have indicated that exosomes can serve as potent therapeutic since they offer low immunogenicity, stability, innate acquired targetability, stimulation of anti-cancer immune responses. Yet, development exosome-based delivery systems remains challenging due to their heterogeneity, yield, limited loading efficiency. Herein, we summarized current application derived from different cells in therapy vitro vivo . We also discussed challenges prospects

Language: Английский

Citations

71
Homologous targeting nanoparticles for enhanced PDT against osteosarcoma HOS cells and the related molecular mechanisms DOI Creative Commons
Yang Wang, Liang Zhang, Guosheng Zhao

et al.

Journal of Nanobiotechnology, Journal Year: 2022, Volume and Issue: 20(1)

Published: Feb. 17, 2022

No prominent advancements in osteosarcoma (OS) treatment have been made the past 20 years. Although photodynamic therapy (PDT) is an emerging technique for cancer therapy, lack of targeted photosensitizers OS severely limits its applications. In this study, we constructed a potential theranostic nanoplatform by using (poly (lactic-co-glycolic) acid (PLGA) nanoparticles (NPs) encapsulating IR780 into shell (PLGA-IR780 NPs), which were further camouflaged with human cell membranes from HOS line (MH-PLGA-IR780 NPs). These NPs showed capacity homologous targeting excellent photoacoustic (PA)/fluorescence (FL) imaging ability. Benefitting their capacity, MH-PLGA-IR780 obviously promoted endocytosis vitro and tumor accumulation vivo, could improve PDT performance under near-infrared (NIR) irradiation. addition, to PA/FL dual-mode ability, had advantages penetrating deeper tissues real-time dynamic distribution monitoring laid foundation clinical applications OS. Moreover, demonstrated that guided significantly induce cells apoptosis ferroptosis via excessive reactive oxygen species (ROS), determined anticancer molecular mechanism was triggered release cytochrome c-activated mitochondrial (endogenous apoptosis), caused activation nuclear receptor coactivator 4 (NCOA4)-mediated ferritinophagy inactivation glutathione peroxidase (GPX4), synergistically leading Lipid-ROS Lipid peroxides (LPOs). Concurrently, NPs-guided also obvious inhibitory effect on growth vivo. results suggest targeting-based provides effective method contributes new promising approach therapy.

Language: Английский

Citations

70
Advanced strategies to evade the mononuclear phagocyte system clearance of nanomaterials DOI Creative Commons
Junjie Lu,

Xiao Gao,

Siyao Wang

et al.

Exploration, Journal Year: 2023, Volume and Issue: 3(1)

Published: Jan. 5, 2023

Nanomaterials are promising carriers to improve the bioavailability and therapeutic efficiency of drugs by providing preferential drug accumulation at their sites action, but delivery efficacy is severely limited a series biological barriers, especially mononuclear phagocytic system (MPS)-the first major barrier encountered systemically administered nanomaterials. Herein, current strategies for evading MPS clearance nanomaterials summarized. First, engineering methods including surface modification, cell hitchhiking, physiological environment modulation reduce explored. Second, disabling blockade, suppression macrophage phagocytosis, macrophages depletion examined. Last, challenges opportunities in this field further discussed.

Language: Английский

Citations

68
Protein corona and exosomes: new challenges and prospects DOI Creative Commons
Morteza Heidarzadeh, Amir Zarebkohan, Reza Rahbarghazi‬

et al.

Cell Communication and Signaling, Journal Year: 2023, Volume and Issue: 21(1)

Published: March 27, 2023

Recent advances in extracellular vesicle (EVs) detection and isolation methods have led to the development of novel therapeutic modalities. Among different types EVs, exosomes (Exos) can transfer signaling biomolecules exhibit several superior features compared whole-cell-based therapies. Therapeutic factors are normally loaded into Exo lumen or attached their surface for improving on-target delivery rate regenerative outcomes. Despite these advantages, there limitations application Exos vivo conditions. It was suggested that a set proteins other biological compounds adsorbed around aqueous phases constitute an external layer named protein corona (PC). Studies shown PC affect physicochemical properties synthetic natural nanoparticles (NPs) after introduction biofluids. Likewise, is generated especially This review article preliminary attempt address interfering effects on bioactivity effects. Video Abstract.

Language: Английский

Citations

63
Bio-Inspired Nanomaterials for Micro/Nanodevices: A New Era in Biomedical Applications DOI Creative Commons
Mohammad Harun‐Ur‐Rashid, Israt Jahan, Tahmina Foyez

et al.

Micromachines, Journal Year: 2023, Volume and Issue: 14(9), P. 1786 - 1786

Published: Sept. 18, 2023

Exploring bio-inspired nanomaterials (BINMs) and incorporating them into micro/nanodevices represent a significant development in biomedical applications. Nanomaterials, engineered to imitate biological structures processes, exhibit distinctive attributes such as exceptional biocompatibility, multifunctionality, unparalleled versatility. The utilization of BINMs demonstrates potential diverse domains micro/nanodevices, encompassing biosensors, targeted drug delivery systems, advanced tissue engineering constructs. This article thoroughly examines the various BINMs, including those originating from proteins, DNA, biomimetic polymers. Significant attention is directed toward these entities subsequent ramifications that arise. review explores biomimicry’s structure–function correlations. Synthesis mosaics include bioprocesses, biomolecules, natural structures. These nanomaterials’ interfaces use functionalization geometric adaptations, transforming delivery, nanobiosensing, organ-on-chip cancer-on-chip models, wound healing dressing mats, antimicrobial surfaces. It provides an in-depth analysis existing challenges proposes prospective strategies improve efficiency, performance, reliability devices. Furthermore, this study offers forward-thinking viewpoint highlighting avenues for future exploration advancement. objective effectively utilize maximize application progression thereby propelling rapidly developing field its promising future.

Language: Английский

Citations

58
Mechano-boosting nanomedicine antitumour efficacy by blocking the reticuloendothelial system with stiff nanogels DOI Creative Commons
Zheng Li,

Yabo Zhu,

Haowen Zeng

et al.

Nature Communications, Journal Year: 2023, Volume and Issue: 14(1)

Published: March 15, 2023

Abstract Nanomedicine has been developed for cancer therapy over several decades, while rapid clearance from blood circulation by reticuloendothelial system (RES) severely limits nanomedicine antitumour efficacy. We design a series of nanogels with distinctive stiffness and investigate how nanogel mechanical properties could be leveraged to overcome RES. Stiff are injected preferentially abrogate uptake capacity macrophages temporarily block RES, relying on inhibition clathrin prolonged liver retention. Afterwards, soft deliver doxorubicin (DOX) excellent efficiency, reflected in high tumour accumulation, deep penetration outstanding In this work, we combine the advantage stiff RES-blockade superiority drug delivery leads optimum effect, which is defined as mechano-boosting strategy. Clinical implications stiffness-dependent also confirmed promoting efficacy commercialized nanomedicines, such Doxil Abraxane.

Language: Английский

Citations

50